Please ensure Javascript is enabled for purposes of website accessibility

Frequently Asked Questions

Does Hormone Therapy Increase the Risk of Blood Clots or Stroke?

Medically Reviewed By: Charytin Maresco, APRN, NP-C

Last Updated: July 28, 2026

For the way hormone therapy is most often prescribed today, the answer is largely no.

Many of the concerns people have about hormone therapy come from the Women's Health Initiative (WHI), a study that looked at older hormone medications called Premarin and Prempro. Those results were often applied to all types of hormone therapy, even though they did not study bioidentical estradiol, especially the forms used as patches, gels, or creams.

Today's research shows that transdermal estradiol, which is absorbed through the skin, works differently than oral estrogen. Because it does not pass through the liver first, it may have a lower risk of blood clots than oral estrogen for many women. The safety of hormone therapy depends on the type of hormone, how it is given, when you start treatment, and your personal health history. Your provider will recommend the option that is safest and most appropriate for you.

Key Points

  • Route matters most. The clot-and-stroke risk is tied to oral estrogen, which passes through the liver and increases the production of clotting proteins. Transdermal estradiol largely bypasses the liver and, at standard doses, does not appear to increase the risk of blood clots or stroke. For this reason, oral estrogen is typically not prescribed for perimenopausal and menopausal women in a risk-aware practice.
  • The scary headlines have a specific source. Most clot-and-stroke fear traces back to the Women’s Health Initiative, which studied oral conjugated estrogen in women averaging about 63 years old — not transdermal estradiol started near menopause.
  • Stroke risk is small in absolute terms. Oral hormone therapy carries a small, statistically real increase in stroke risk that is concentrated in older women and higher doses. Low-dose transdermal therapy appears lower-risk.
  • Timing is a major lever. Starting before age 60 or within 10 years of menopause carries the most favorable overall risk-to-benefit ratio.
  • For men, the concern is different. Testosterone can raise red blood cell count (hematocrit), which can thicken the blood — the reason hematocrit is monitored on therapy.
  • Your history changes the math. A personal or family history of clots, stroke, or an inherited clotting disorder shifts the calculation and must be reviewed before starting.

Understanding Blood Clots, Stroke, and Hormone Therapy

Two different risks often get lumped together. Venous thromboembolism (VTE) refers to clots that form in the veins — a deep vein thrombosis (DVT), usually in the leg, or a pulmonary embolism (PE), when a clot travels to the lungs. Stroke is a problem in the arteries supplying the brain, most commonly when blood flow is blocked (ischemic stroke). Estrogen influences both systems, but not equally and not in every form.

The mechanism behind the clotting risk is well understood. When estrogen is swallowed as a pill, it is absorbed through the gut and routed through the liver before reaching the rest of the body — the “first-pass” effect. The liver responds by producing more clotting factors and shifting the blood toward a more clot-prone state. Pooled data show that oral hormone therapy roughly doubles the risk of VTE compared with no therapy. Estrogen absorbed through the skin skips that first liver pass and has minimal effect on those clotting markers, which is why transdermal estradiol behaves so differently from an estrogen pill.

Much of the public fear dates to 2002, when one arm of the Women’s Health Initiative was stopped early after showing increased clots, stroke, and other risks. That trial is important, but it tested a single regimen — oral conjugated equine estrogen with a synthetic progestin — in women whose average age was about 63, many of them more than a decade past menopause. Later reanalysis by age showed that women who started near menopause had a far more favorable profile, and the findings do not automatically transfer to transdermal estradiol or to younger women starting at the right time. The risk was real for the population studied; the problem was treating one result as if it applied to every hormone, every route, and every age.

Why the Delivery Method Changes the Risk

If there is one practical takeaway in this entire discussion, it is that how estrogen enters your body changes its risk profile more than almost any other single factor. This is the reason a careful provider does not just decide whether to use hormone therapy — they decide which route.

  • Transdermal estradiol (patch, gel, cream): Absorbed through the skin, bypassing first-pass liver metabolism. Current evidence indicates that at standard doses it does not increase the risk of blood clots, and — unlike oral estrogen — it does not appear to raise stroke risk either. It is the preferred route for women with any clotting or cardiovascular risk factors, and the default choice in a risk-aware practice.
  • Oral estrogen (pill): Convenient and well-studied, but the first-pass liver effect raises clotting factors and carries the clearest increase in blood clot risk along with a small increase in stroke risk. This is the route responsible for most of hormone therapy’s clot-and-stroke reputation — and it is typically not prescribed for perimenopausal and menopausal women in a risk-aware practice, where transdermal delivery is preferred.
  • Vaginal estrogen (local): Used for genitourinary symptoms such as dryness or discomfort, it is absorbed in such small amounts that it is generally considered safe even for many women who cannot use systemic hormone therapy.

The progestogen component matters too. When a woman with a uterus uses systemic estrogen, a progestogen is needed to protect the uterine lining. Micronized progesterone (the bioidentical form) has been associated with a more favorable risk profile than some older synthetic progestins, which is part of why bioidentical formulations are often preferred when estrogen must be paired with a progestogen.

For men, hormone therapy raises a separate, route-independent concern. Testosterone stimulates red blood cell production, and if hematocrit (the proportion of red cells in the blood) climbs too high, the blood becomes more viscous, and clot risk rises. This is manageable and predictable: it is caught with routine bloodwork, and addressed by adjusting the dose, changing the delivery method, or, occasionally, donating blood. It is a reason testosterone therapy requires monitoring — not a reason to avoid it in appropriately screened men.

Who It’s For And Who Should Be Cautious

Hormone therapy’s clot-and-stroke risk is low for many people and substantial for a smaller group. The point of a thorough evaluation is to tell which group you are in before anything is prescribed.

Generally lower-risk candidates:

  • Healthy women starting near menopause (before age 60 or within 10 years of their last period), particularly using transdermal estradiol.
  • Women who need local vaginal estrogen for genitourinary symptoms, even some who cannot use systemic therapy.
  • Men with clinically low testosterone and a normal baseline hematocrit, who are willing to monitor their bloodwork.

Caution — or a more individualized approach:

  • A personal history of blood clots (DVT or PE), stroke, or transient ischemic attack (TIA).
  • A known inherited clotting disorder, such as Factor V Leiden or a prothrombin gene mutation, or a strong family history of clots.
  • Migraine with aura, uncontrolled high blood pressure, active cardiovascular disease, smoking, significant obesity, or prolonged immobility.
  • For men: a significantly elevated hematocrit, untreated sleep apnea, or other factors that compound clotting risk.

For many people in the caution group, hormone therapy is not automatically off the table. It often means choosing a different delivery method, using the lowest effective dose, or relying on local therapy. For some, the safest option is to avoid systemic estrogen altogether. That decision is individualized and made after reviewing your complete medical history.

Risks, Side Effects, and Monitoring

Responsible hormone care is built around lowering the very risks this article describes, then watching for them over time:

  • Route selection as risk reduction: Choosing transdermal estradiol for anyone with clotting or cardiovascular risk factors is one of the simplest and most effective ways to keep the risk low.
  • Baseline assessment: Personal and family history of clots and stroke, blood pressure, and relevant labs are reviewed before starting, with clotting-disorder screening considered when history warrants it.
  • Ongoing monitoring: Symptom check-ins and periodic labs. For men taking testosterone, your provider will monitor your hematocrit and hemoglobin because testosterone can increase red blood cell production, a condition called erythrocytosis. This is a known effect of testosterone and is monitored with routine blood work. However, testosterone is not the only cause of elevated hematocrit or hemoglobin. Living at a high altitude, untreated sleep apnea, COPD, smoking, and certain other medical conditions can also raise these levels. Your provider will review your results in the context of your overall health and determine if any changes are needed. Blood pressure is also monitored for everyone receiving systemic hormone therapy.
  • Situational caution: Clot risk rises temporarily around major surgery, serious injury, or long periods of immobility (including long-haul travel). Tell your provider about planned procedures so therapy can be adjusted if needed.
  • Dose and reassessment: The lowest effective dose is used, and the plan is revisited over time rather than left on autopilot.

Safety

Blood clots and stroke are medical emergencies. Call your local emergency number right away if you notice the warning signs below — do not wait to see if they pass. Face drooping on one side, Arm or leg weakness or numbness (especially on one side), Speech that is slurred or hard to understand — and Time to call for emergency help immediately. Also seek urgent care for sudden confusion, sudden trouble seeing, loss of balance, or a sudden, severe headache unlike any you’ve had before.

Swelling, pain, warmth, or redness in one leg or calf (possible DVT); or sudden shortness of breath, chest pain that worsens with breathing, a racing heartbeat, or coughing up blood (possible pulmonary embolism). If you are currently taking medications for blood pressure, clotting, hormones, or any other condition, any changes should be coordinated with your prescribing physician. We work collaboratively with your healthcare team to ensure safe, integrated care. Never adjust or discontinue medications without medical guidance.

Sources and Citations

This content is for educational purposes and does not substitute personalized medical advice.

Charytin Maresco, APRN, NP-C

Charytin Maresco, APRN, NP-C, is a board-certified nurse practitioner specializing in hormone health, healthy aging, and personalized metabolic care. For more than 17 years, she has helped men and women navigate perimenopause, menopause, and andropause, restoring energy, sleep, mood, libido, and whole-body balance through evidence-informed BHRT and personalized wellness care.

Areas Served

Charys Medical Boutique is located in Stuart, FL, and serves patients throughout the Treasure Coast and Southeast Florida area as well as virtually in the greater Colorado area and New York area. These areas include but are not limited to Martin County, FL, St. Lucie County, FL, and the cities of Stuart, FL, Palm City, FL, Jensen Beach, FL, Hobe Sound, FL, Sewall's Point, FL, Port Salerno, FL, Rio, FL, Port St. Lucie, FL, and Fort Pierce, FL, as well as Denver, CO, Boulder, CO, Colorado Springs, CO, Fort Collins, CO, Aurora, CO, and Castle Rock, CO. In New York, the areas served include Long Island, Nassau County, Suffolk County, Staten Island, Queens, Brooklyn, the Bronx, Yonkers, Poughkeepsie, and Scarsdale.

menuchevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram